Product Program year 2025 Source: CMS Open Payments

Dilaudid

Drug Anesthetics

NDC 76045-009-10

Open in the dashboard

General payments

$13,302

8 payments

Research payments

$0

0 payments

Through program year 2025, $13,302 in general payments and $0 in research payments were reported against Dilaudid (Anesthetics).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2025 General $13,232 6
2021 General $70 2

Breakdown

Who paid General payments · program years 2021–2025
  1. Fresenius Kabi USA, LLC $13,302 8 payments
Top recipients General payments · program year 2025
  1. Cleveland Clinic Hospital Teaching hospital · OH $11,000 83% · 1 payment
  2. Adrian Gelb Anesthesiology · San Francisco, CA $1,200 9% · 1 payment
  3. Asokumar Buvanendran Interventional Pain Medicine · Chicago, IL $750 6% · 1 payment
  4. Joelle Lieman Obstetrics & Gynecology · Brighton, MA $144 1% · 1 payment
  5. Satya Krishna Ramachandran Anesthesiology · Boston, MA $90 <1% · 1 payment

The top 5 of 6 recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Anesthesiology $1,338 60% · 3 practitioners
  2. Interventional Pain Medicine Pain Medicine $750 34% · 1 practitioner
  3. Obstetrics & Gynecology $144 6% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2025
  1. Ohio $11,048 83% · 2 recipients
  2. California $1,200 9% · 1 recipient
  3. Illinois $750 6% · 1 recipient
  4. Massachusetts $234 2% · 2 recipients

Each share is of general payments naming this product in 2025 where a state was reported.

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

83

Prescriptions dispensed, refills included

Drug cost

$42,163

Paid at the pharmacy, in all

Prescribers

6

With 11 or more claims of it

Medicare Part D drugs matched to Dilaudid, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Dilaudid Hydromorphone Hcl Same name 6 83 $42,163

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 6 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Michael Desch Physician Assistant NJ 19 $9,752 None on record
Mark Kostin Family Practice NY 16 $14,955 None on record
Katja Swartz Nurse Practitioner VA 13 $2,533 None on record
Larry Neuman Internal Medicine NY 12 $7,097 None on record
Heikki Uustal Physical Medicine and Rehabilitation NJ 12 $2,809 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See all 6 in the dashboard with a free account

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to Dilaudid
Billing code Providers Services Paid by Medicare
Injection, hydromorphone, 0.1 mg J1171 13 423,427 $27,413

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

8 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record